JP2019514974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514974A5 JP2019514974A5 JP2018558238A JP2018558238A JP2019514974A5 JP 2019514974 A5 JP2019514974 A5 JP 2019514974A5 JP 2018558238 A JP2018558238 A JP 2018558238A JP 2018558238 A JP2018558238 A JP 2018558238A JP 2019514974 A5 JP2019514974 A5 JP 2019514974A5
- Authority
- JP
- Japan
- Prior art keywords
- weeks
- dose
- vedolizumab
- administered
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022107008A JP7474287B2 (ja) | 2016-05-04 | 2022-07-01 | 炎症性腸疾患の治療を目的とする三剤併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662331813P | 2016-05-04 | 2016-05-04 | |
| US62/331,813 | 2016-05-04 | ||
| PCT/US2017/031089 WO2017192867A1 (en) | 2016-05-04 | 2017-05-04 | Triple combination therapy for treating inflammatory bowel disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022107008A Division JP7474287B2 (ja) | 2016-05-04 | 2022-07-01 | 炎症性腸疾患の治療を目的とする三剤併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514974A JP2019514974A (ja) | 2019-06-06 |
| JP2019514974A5 true JP2019514974A5 (enExample) | 2020-06-25 |
| JP7162533B2 JP7162533B2 (ja) | 2022-10-28 |
Family
ID=58710089
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558238A Active JP7162533B2 (ja) | 2016-05-04 | 2017-05-04 | 炎症性腸疾患の治療を目的とする三剤併用療法 |
| JP2022107008A Active JP7474287B2 (ja) | 2016-05-04 | 2022-07-01 | 炎症性腸疾患の治療を目的とする三剤併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022107008A Active JP7474287B2 (ja) | 2016-05-04 | 2022-07-01 | 炎症性腸疾患の治療を目的とする三剤併用療法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10918716B2 (enExample) |
| EP (1) | EP3452070A1 (enExample) |
| JP (2) | JP7162533B2 (enExample) |
| MA (1) | MA44864A (enExample) |
| WO (1) | WO2017192867A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| UY34054A (es) * | 2011-05-02 | 2012-11-30 | Millennium Pharm Inc | FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 |
| EP3224280A1 (en) | 2014-11-26 | 2017-10-04 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| JP7162533B2 (ja) | 2016-05-04 | 2022-10-28 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | 炎症性腸疾患の治療を目的とする三剤併用療法 |
| WO2017218434A1 (en) | 2016-06-12 | 2017-12-21 | Millennium Pharmaceuticals, Inc. | Method of treating inflammatory bowel disease |
| US20230096620A1 (en) * | 2019-04-17 | 2023-03-30 | Millennium Pharmaceuticals, Inc. | Alpha4beta7 inhibitor and il-23 inhibitor combination therapy |
| EP4068295B1 (en) * | 2021-03-29 | 2025-04-30 | Siemens Healthineers AG | Clinical decision support system for estimating drug-related treatment optimization concerning inflammatory diseases |
| US20240254243A1 (en) * | 2021-06-17 | 2024-08-01 | Prometheus Laboratories Inc. | Systems and methods for improved targeted therapy |
| CN113402583B (zh) * | 2021-06-19 | 2023-03-21 | 江西农业大学 | Qgk三肽及其应用 |
| CN114225025B (zh) * | 2021-12-29 | 2022-07-26 | 贵州酵德生物科技有限公司 | 含有益生菌的制剂在治疗肠胃疾病中的应用 |
| EP4720125A1 (en) | 2023-05-30 | 2026-04-08 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| EP4762093A1 (en) | 2023-08-14 | 2026-06-24 | Paragon Therapeutics, Inc. | Alpha 4 beta 7 integrin binding proteins and methods of use |
| US20260015407A1 (en) | 2024-07-15 | 2026-01-15 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory fusion proteins and related methods |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE366809T1 (de) | 1995-02-10 | 2007-08-15 | Millennium Pharm Inc | Addressine der schleimhaut und der blutgefässe und ihre verwendung |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| EP1948691A1 (en) | 2005-11-17 | 2008-07-30 | Millennium Pharmaceuticals, Inc. | HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN |
| UY34054A (es) | 2011-05-02 | 2012-11-30 | Millennium Pharm Inc | FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| EP3224280A1 (en) | 2014-11-26 | 2017-10-04 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| JP6904905B2 (ja) | 2014-12-24 | 2021-07-21 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗α４β７インテグリン抗体による治療の結果の予測 |
| JP7162533B2 (ja) | 2016-05-04 | 2022-10-28 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | 炎症性腸疾患の治療を目的とする三剤併用療法 |
-
2017
- 2017-05-04 JP JP2018558238A patent/JP7162533B2/ja active Active
- 2017-05-04 MA MA044864A patent/MA44864A/fr unknown
- 2017-05-04 EP EP17724180.9A patent/EP3452070A1/en active Pending
- 2017-05-04 US US16/098,572 patent/US10918716B2/en active Active
- 2017-05-04 WO PCT/US2017/031089 patent/WO2017192867A1/en not_active Ceased
-
2021
- 2021-01-19 US US17/152,585 patent/US12246064B2/en active Active
-
2022
- 2022-07-01 JP JP2022107008A patent/JP7474287B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2017537105A5 (enExample) | ||
| JP2021502961A5 (enExample) | ||
| JP2019533646A5 (enExample) | ||
| JP2013533858A5 (enExample) | ||
| JP2015525798A5 (enExample) | ||
| JP2015187125A5 (enExample) | ||
| JP2018514510A5 (enExample) | ||
| Gabay et al. | Biological agents in monotherapy for the treatment of rheumatoid arthritis | |
| JP2021535161A5 (enExample) | ||
| JP2022532356A5 (enExample) | ||
| JP2023517535A5 (enExample) | ||
| JP2024069230A5 (enExample) | ||
| RU2020134307A (ru) | Режимы дозирования мелфлуфена для раковых заболеваний | |
| JP2024023347A5 (enExample) | ||
| JP2019519584A5 (enExample) | ||
| JP2023539625A5 (enExample) | ||
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JP7370357B2 (ja) | 医薬組成物 | |
| JP2022513029A5 (enExample) | ||
| CN115052628A (zh) | 抗pd-1抗体在治疗肿瘤中的用途 | |
| CN115702023A (zh) | 化脓性汗腺炎的治疗 | |
| Theede et al. | Biologic therapy in inflammatory bowel disease | |
| JP2017515843A (ja) | 抗ｅｇｆｒ治療薬の投与量および投与 | |
| CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 |